Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | PREP | P48147 | 4/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143921 | 0.83 | PREP (0.46) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL12017833 | 0.81 | CA1 (0.59) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL704912 | 0.80 | CA12 (0.58) | CA12CA1CA9PREPNPC1 | |
| SCHEMBL11460575 | 0.80 | CA12 (0.44) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL30186537 | 0.80 | CA12 (0.58) | CA12CA1CA9PREPNPC1 | |
| SCHEMBL2523819 | 0.79 | CA12 (0.56) | CA12CA1CA9PREPNPC1 | |
| SCHEMBL6811874 | 0.79 | CA12 (0.56) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL7759839 | 0.79 | CA12 (0.56) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL12581975 | 0.77 | CA12 (0.55) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL2221888 | 0.77 | CA12 (0.55) | CA12CA1CA9PREPNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0963996-B9 | Transition metal compound, catalyst component and catalyst for olefin polymerization and process for the preparation of alpha-olefin polymer | JAPAN POLYCHEM CORP (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-0963996-B1 | Transition metal compound, catalyst component and catalyst for olefin polymerization and process for the preparation of alpha-olefin polymer | JAPAN POLYCHEM CORP (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6509426-B2 | Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability | JAPAN POLYCHEM CORPORATION (JP) | 2003-01-21 | — | — | US | disclosed |
| US-20010023296-A1 | Novel transition metal compound, catalyst component for olefin polymerization and process for the preparation of alpha-olefin polymer | JAPAN POLYCHEM CORPORATION (JP) | 2001-09-20 | — | — | US | disclosed |
| US-6218558-B1 | BRIDGED OXYGEN-, NITROGEN- OR SULFUR-CONTAINING METALLOCENE CATALYST CONTAINING AT LEAST CYCLOPENTADIENE RING FUSED TO A C7-10 RING | JAPAN POLYCHEM CORPORATION (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-0963996-A2 | Novel transition metal compound, catalyst component for olefin polymerization and process for the preparation of alpha-olefin polymer | Japan Polychem Corporation (JP) | 1999-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023296-A1 | Novel transition metal compound, catalyst component for olefin polymerization and process for the preparation of alpha-olefin polymer | OSTC, TCP1, COG1 | CA12 1947/4885CA1 1701/4885CA9 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.